NCT01018693View on ClinicalTrials.gov

A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Seasonal Allergic Rhinitis
Interventions
DRUG

VAK694; Alutard Avanz SQ

DRUG

VAK694 placebo infusion; Alutard Avanz SQ

DRUG

VAK694 placebo infusion; Saline

Trial Locations (1)

Unknown

Novartis Investigator Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY